What Are Wall Street Analysts' Target Price for IDEXX Laboratories Stock?

Core Insights - IDEXX Laboratories, Inc. is a leading company in the pet healthcare sector, with a market capitalization of $55.7 billion, focusing on veterinary products and services for various animal markets [1] Performance Overview - Over the past year, IDXX shares have increased by 64.7%, significantly outperforming the S&P 500 Index, which rose by 10.5% [2] - Year-to-date in 2025, IDXX stock is up 66.7%, compared to the S&P 500's 11.2% increase [2] Comparison with Industry Peers - IDXX's performance is also superior to the SPDR S&P Health Care Equipment ETF (XHE), which has declined by 9.3% over the past year [3] - On a year-to-date basis, IDXX's double-digit returns contrast with the ETF's 8.1% losses [3] Financial Results - On November 3, IDXX reported Q3 results, with an EPS of $3.40, exceeding Wall Street's expectation of $3.14 [4] - The company's revenue for the quarter was $1.11 billion, surpassing the forecast of $1.07 billion [4] - For the full year, IDXX expects EPS to be between $12.81 and $13.01, with revenue projected between $4.27 billion and $4.30 billion [4] Analyst Expectations - Analysts predict a 21.2% growth in IDXX's EPS for the current fiscal year, estimating it to reach $12.93 on a diluted basis [5] - IDXX has consistently beaten consensus estimates in the last four quarters, indicating strong performance [5] - Among 13 analysts, the consensus rating for IDXX is a "Moderate Buy," with seven "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] Price Targets - Analyst Chris Schott from JPMorgan Chase & Co. maintains a "Buy" rating on IDXX with a price target of $775, suggesting a potential upside of 12.4% [6] - The mean price target is $785.27, indicating a 13.9% premium to current levels, while the highest target of $830 suggests a 20.4% upside potential [6]